Axe Compute Inc. quarterly report, Q2 FY2021

Business context and reporting period

This is Predictive Oncology Inc.’s unaudited Form 10-Q for the quarter and six months ended June 30, 2021. The filing identifies the registrant as Predictive Oncology Inc. (Nasdaq: POAI), not Axe Compute Inc.; verify the company identity associated with this request.

The company operates in precision oncology and clinical research (Helomics), protein formulation and research services (Soluble), and medical fluid-disposal products (Skyline). Management said it planned to focus resources on Helomics and precision medicine.

Key financial metrics

• Cash and liquidity: Cash and cash equivalents were $44.9 million at June 30, 2021, versus $678,332 at December 31, 2020. Current assets were $45.6 million and current liabilities $3.2 million.
• Cash flow: Operating cash use was $5.5 million for the six months, compared with $6.7 million in 2020. Investing activities used $634,000; financing activities provided $50.4 million. Cash increased by $44.2 million.
• Debt and liabilities: No notes payable remained at June 30, following repayment in March. Total liabilities were $3.8 million, including lease liabilities.
• Capitalization: Common shares outstanding were 65.3 million at June 30, compared with 19.8 million at year-end 2020; 65.4 million were outstanding August 6. The company reported 31.7 million warrants outstanding at June 30.

Material changes versus prior comparable period

• Q2 revenue increased 92% year over year; six-month revenue rose 32%. Skyline generated most revenue: $306,136 in Q2 and $570,388 for the half-year. Soluble contributed $48,985 in first-half revenue; Helomics contributed $9,151.
• Losses narrowed year over year. The filing attributes lower G&A expense partly to reduced share-based compensation and professional fees; lower interest and debt-related costs also helped after debt repayment. Operating and development costs rose in part because of staffing and AI computing costs.
• First-half gross margin declined to 62% from 63%, although Q2 margin improved to 59% from 53%. Skyline’s reported gross margin was 66% for Q2 and 75% for the half-year, versus 75% and 76%, respectively, in 2020.
• Financing substantially increased cash and shares. January–February offerings generated $31.1 million net; the June offering generated $19.4 million net. The company also received $4.5 million from warrant exercises and repaid $5.9 million of debt and related amounts in March.

Outlook, risks and unusual items

• Management said existing resources were expected to support its operating plan for the next 12 months and beyond, while also retaining the option to seek additional capital or reduce costs. The company continued to report operating losses and negative operating cash flow; additional equity financing could be dilutive.
• The remaining equity-line capacity was $9.2 million at quarter-end, subject to market conditions, other restrictions, and shareholder approval. The June offering warrants, covering up to 15.5 million shares, were exercisable only after an increase in authorized shares.
• COVID-19 was reported to have disrupted STREAMWAY parts supply and order fulfillment, reduced onsite staffing and production efficiency, and constrained hospital sales activity. The duration and financial effects remained uncertain.
• Other risks include competition, regulatory requirements, intellectual-property protection, dependence on key personnel, execution of partnerships and acquisitions, and possible future goodwill impairment. The filing reported no legal proceedings.
• The company reported that a prior material weakness in internal control over financial reporting was remediated as of June 30, 2021; disclosure controls were deemed effective.
• CEO J. Melville Engle took office in March 2021. Former CEO Carl Schwartz’s separation included 100,000 shares and vesting of 300,000 restricted stock units.

Important facts for investors to verify

1. Confirm the registrant identity: the supplied metadata names Axe Compute Inc., but this filing is for Predictive Oncology Inc. (POAI).
2. Check the outcome of the August 10, 2021 special meeting, particularly approval of the authorized-share increase and equity-line issuance; the provided filing text does not state the voting results.
3. Assess potential dilution from the large warrant and equity financing overhang, and confirm the status and terms of any warrant exercises.
4. Monitor operating cash burn, revenue conversion—especially Helomics—and whether management’s stated funding runway remains achievable.
5. Track COVID-related supply and sales disruption, and the company’s progress toward its stated precision-medicine focus.